Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 4, Issue 2, 2002, Pages 70-73

  Masand, Prakash S ^a,d   Wang, Xiaohong ^b   Gupta, Sanjay ^c   Schwartz, Thomas L ^b   Virk, Subhdeep ^b   Hameed, Ahmad ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c Olean General Hospital   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2542437816     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/PCC.v04n0205     Document Type: Article

References (19)

1. Ghaemi SN, Sachs GS, Baldassano CF. et al. Acute treatment of bipolar disorder with adjunctivc risperidone in outpatients. Can J Psychiatry 1997; 42;196-199
2. McElroy SL, Frye M, Denicoff K, et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998;49:119-122
3. Frye MA. Kctter TA, Altshuler LL. et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998;48:91-104
4. Apter JT, Cantillon M. Goldstein JM. et al. Efficacy, safety, and tolerability of seroquel (quetiapine fumarate) in elderly patients with psychotic disorders. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology: December 8-12, 1997; Waikoloa. Hawaii
5. Keck P. Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998;140:173-184
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National institute of Mental Health: 1976;218-222
7. Drug Topics: Red Book. Montvale, NJ: Medical Economics; 1998
8. Ghaemi SN, Goodwin FK. Use of atypical antipsycholics in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999;19:354-361
9. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
10. Tonen M. Zarate CA. Centorrino F, et al. Risperidone in the treatment of mania. J Clin Psychiatry 1996;57:249-253
11. Ghaemi SN, Sachs GS. Long-term risperidone treatment in bipolar disorder: 6-month follow up. Tnt Clin Psychopharmacol 1997;12:333-338 :
12. Dwight MM, Keck PE, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554-555
13. Sajotovic M, DiGiovanni SK. Basstani B. et al. Risperidone therapy ' in treatment refractory acute bipolar and schizoaffective mania. Psychopharmaeol Bull 1996;32:55-61
14. Sachs GS. Grossman F. Okamoto A. et al. Safety and efficacy of risperidone versus placebo as add-on therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder. In: New Research Abstracts of the 153rd Annual Meeting of the American Psychiatric Association; May 17. 2000; Chicago, III. Abstract NR492:191
15. Segal J, Berk M, Brook S. Risperidone compared with both lithium and halopcridol in mania: double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-180
16. Tohen M. Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
17. Tohen M, Jacobs TO, Grandy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
18. Baker RW. Tohen MF. Altshuler LL, et al. Olanzapine versus divalproex sodium for mania: a 47-week study. Presented at the 155th annual meeting of the American Psychiatric Association: May 18-23, 2002; Philadelphia. Pa
19. Tohen MF. Chengappa KNR, Suppes P, el al. Olanzapine combined with lithium or valproate for relapse prevention of bipolar disorder: an 18-month study. Presented at the 155th annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa